Priovant Reports Positive Trial Results for Dermatomyositis in NEJM

AI Summary

Priovant Pharmaceuticals announced positive results from its clinical trial for patients with dermatomyositis, as reported in the New England Journal of Medicine (NEJM). The specific data points on efficacy or P-values were not disclosed, but the company highlighted the trial's importance for this rare autoimmune disease. These results may influence the market's perception of the company and its stock performance pending further regulatory review. The trial's success could drive increased investor interest and potential stock price appreciation.